论文部分内容阅读
中国药学会“发展新药研究讨论会”于10月12～17日在杭州市举行。会议分发了论文材料35篇,安排42人作了学术报告和专题发言。美国加州大学药化室主任 M.Wolff 教授应邀在会上作了“甾体药物定量构效关系”和“受体结合”的报告。这次讨论会内容包括三方面:(1)总结新药研究的经验教训:(2)新药设计的思想源泉和理论基础;(3)新药研究的科学管理。会议开得很生动活泼,大家都能各抒己见,畅所欲言。代表们普遍认为,发展新药研究的关键在于基础研究,在于方法学上的突破。要想在新药研究上有所突破,必须先在有关生物学科领域有所突破,建立新的筛选方法和实验模型,生化药理、免疫学,临床学以及酶学,受体学说等有关分子生物学是基础研究的几个重要方面。在这次会上.QSAR 方面的专题报告有10篇之多,由于它在我国还刚开始应用,需要继续普及有关知识,结合新药研究加以运用。还需要健全临床前药理包括药物代
Chinese Pharmaceutical Association “Development of New Drug Research Symposium ” was held in Hangzhou on October 12 ~ 17. The conference distributed 35 papers and arranged for 42 people to make academic reports and special presentations. Professor M.Wolff, director of the pharmacy office of the University of California, USA, was invited to give a speech at the meeting on the quantitative structure-activity relationship of steroidal drugs and receptor binding. The seminar includes three aspects: (1) to sum up the experience and lessons of new drug research: (2) the source and theoretical basis of new drug design; (3) the scientific management of new drug research. The meeting opened very lively, we all can express their opinions, speak their minds. The deputies generally agreed that the key to the development of new drug research lies in fundamental research, which is a breakthrough in methodology. In order to make breakthroughs in the research of new drugs, we must first make breakthroughs in the field of biology and establish new screening methods and experimental models, biomolecular pharmacology, immunology, clinical science, and enzyme, receptor theory and other related molecular biology It is a few important aspects of basic research. At this meeting, as many as 10 special reports on QSAR have been published, as it has just started to be applied in our country, we need to continue to popularize relevant knowledge and apply it in combination with the research on new drugs. Also need to improve preclinical pharmacology, including drug generation